Hikma Ventures has taken a minority stake in Birmingham-based health technology firm Rem3dy Health to fund its expansion across seven Middle Eastern markets.
The investment follows a 61% revenue increase at Rem3dy Health to £10.2m, supported by retail distribution through Boots, Costco and Holland and Barrett. The transaction builds on a commercial agreement to export British-made personalised nutrition products across the Middle East and North Africa.
Hikma will introduce the company’s 3D-printed nutritional gummies into the UAE, Saudi Arabia and Jordan in early 2027. Rollouts across Qatar, Kuwait, Oman and Bahrain will follow, marking the London-listed pharmaceutical group’s initial entry into the consumer health and wellness sector.
Melissa Snover, founder of Rem3dy Health, launched the business in 2019, developing a manufacturing platform that combines 3D printing, material science and artificial intelligence. The group holds 29 patents for its seven-layer gummies, which are produced in the West Midlands to target areas including sleep, cognitive function and gut health.
Lana Ghanem, Director of corporate development at Hikma Pharmaceuticals and managing director of Hikma Ventures, said: "At Hikma, we are constantly looking for innovative companies that are shaping the future of healthcare. Rem3dy Health combines differentiated technology, strong consumer engagement and a compelling vision for personalised wellness.
"This investment reflects Hikma Ventures’ strategy of backing high-growth healthcare businesses that not only have significant commercial potential but can also create strategic value across Hikma’s businesses and markets."
Snover added: "Having Hikma invest in Rem3dy as well as partner with us commercially is particularly meaningful because it connects capital investment with a genuine route to market. We have spent the past seven years developing our technology, building our intellectual property and scaling our manufacturing capabilities here in Birmingham.
"This partnership gives us the opportunity to take products developed and manufactured in the UK into new international markets, supported by the expertise and reach of one of the world’s most established pharmaceutical businesses. It is a significant milestone for our team and a great example of how British innovation and advanced manufacturing can create opportunities for international growth."











